Jale Karolyi-Oezguer

Drugging an undruggable pocket on KRAS

M. Koegl, S. Fesik, A. Waterson, 2019, Proceedings of the National Academy of Sciences.

Synthesis of MDM2-p53 Inhibitor BI-0282 via a Dipolar Cycloaddition and Late-Stage Davis–Beirut Reaction

Harald Weinstabl, A. Gollner, Jale Karolyi-Oezguer, 2022, Organic process research & development.

Reply to Tran et al.: Dimeric KRAS protein–protein interaction stabilizers

M. Koegl, S. Fesik, A. Waterson, 2020, Proceedings of the National Academy of Sciences.

Discovery of Novel Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-one Compounds as Chemically Stable and Orally Active Inhibitors of the MDM2-p53 Interaction.

Markus J. Bauer, P. Ettmayer, D. Rudolph, 2016, Journal of medicinal chemistry.

BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design

William Farnaby, Peter Greb, Michael Galant, 2019, Nature Chemical Biology.

Targeted Synthesis of Complex Spiro[3H‐indole‐3,2′‐pyrrolidin]‐2(1H)‐ones by Intramolecular Cyclization of Azomethine Ylides: Highly Potent MDM2–p53 Inhibitors

Julian E. Fuchs, Joachim Broeker, D. Rudolph, 2018, ChemMedChem.

BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design

M. Koegl, T. Owen-Hughes, P. Ettmayer, 2019 .

BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design

M. Koegl, T. Owen-Hughes, P. Ettmayer, 2019 .

Targeting cancer with small molecule pan-KRAS degraders

M. Koegl, A. Ciulli, W. Farnaby, 2024, bioRxiv.